View source for Hovione

{{Short description|Pharmaceutical company}}
{{Multiple issues|
{{Advert|date=October 2021}}
{{Citation style|date=May 2022}}
}}
{{Infobox company
| name = Hovione
| logo = Logo Hovione.svg
| logo_caption =
| image =
| image_caption =
| trading_name =
| native_name =
| native_name_lang =  <!-- Use ISO 639-1 code, e.g. "fr" for French. For multiple names in different languages, use {{lang|[code]|[name]}} instead. -->
| romanized_name =
| former_name =
| former type =
| type = [[Privately held company|Private]]
| traded_as =
| industry =
| genre =             <!-- Only used with media and publishing companies -->
| fate =
| predecessor =       <!-- or: | predecessors = or | predecessor = -->
| successor =         <!-- or: | successors = -->
| foundation =        {{start date|1959}}
| founder =           <!-- or: | founders = -->
| defunct =           <!-- {{end date|YYYY|MM|DD}} -->
| location_city =
| location_country =
| locations =         <!-- Number of locations -->
| area_served =
| key_people = {{unbulleted list|Jean-Luc Herbeaux (CEO)|Diane Villax (Founder-Chairman)|Elie Vannier (Chairman)|Guy Villax (Non-Executive Board Member)}}
| products = {{unbulleted list|Pharmaceutical Fine Chemicals|Off-Patent APIs|Inhalation|Dry Powder inhalers}}
| brands =
| production =
| services = {{unbulleted list|Contract Manufacturing Services|Drug Substance|Particle Engineering||Drug Product|Drug Product Intermediate|Drug Product Formulation|Drug Product Inhalation}}
| revenue =
| operating_income =
| net_income =
| aum =               <!-- Only for financial-service companies -->
| assets =
| equity =
| owner =             <!-- or: | owners = -->
| num_employees = 2000 (2022)
| parent =
| divisions =
| subsid =
| homepage =
| footnotes =
| bodystyle =
}}
'''Hovione''' is a Contract Development and [[Manufacturing]] Organization (CDMO) with services for drug substance, drug product intermediate and drug product. The company has four [[FDA]] inspected sites in the [[United States]], [[Portugal]], [[Ireland]] and [[China]] development laboratories in [[Lisbon]], [[Portugal]] and [[New Jersey]], [[United States|USA]]. Hovione is also present in the [[inhalation]] area, and provides a complete range of services, from [[active pharmaceutical ingredient]]s (APIs), formulation development and devices. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified [[B Corporation (certification)]], is a member of Rx-360<ref>{{Cite web |title=Rx-360 |url=https://rx-360.org/membership-overview/}}</ref> and EFCG.<ref>{{Cite web |title=EFCG |url=https://efcg.cefic.org/about-us/membership/}}</ref>
== History ==
[[File:Ivan Villax.jpg|thumb|Ivan Villax - 1950]]
Hovione was established in Portugal in 1959 by Ivan Villax with his wife, Diane Villax, and two other Hungarian refugees: [[Miklós Horthy Jr.|Nicholas de Horthy]] and Andrew Onody, the first two letters of the three founders’ names: HO, VI and ON were used to create the name Hovione.<ref>{{Cite web |title=History of Hovione |url=https://www.hovione.com/about-hovione/history-hovione |access-date=2022-05-09 |website=Hovione |date=23 July 2014 |language=en}}</ref>
Hovione continues to be a privately held company with 5 plants - in [[Portugal]] (1969), [[Macao]] (1986), and [[New Jersey]] (2001) expanded in 2016,<ref>[http://www.in-pharmatechnologist.com/Processing/Hovione-to-build-US-plant-for-Vertex-s-cystic-fibrosis-drugs/  “Hovione to build US plant for Vertex's cystic fibrosis drugs” - in-Pharma Technologist]</ref> [[Taizhou, Zhejiang|Taizhou]] in mainland [[China]] (2008) and [[Cork (city)|Cork]], Ireland (2009) - have a total [[Chemical reactor|reactor]] capacity of 1300 m³ and 1100 people worldwide. Since Hovione started operations in 1959, the company has patented more than 100 innovative chemical processes and produced industrially over 45 different APIs. All Hovione sites have been successfully inspected either by the FDA, [[European Medicines Agency|the European Medicines Agency]] or the [[Pharmaceuticals and Medical Devices Agency|PMDA]] Japanese agency.<ref>[http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0470627670.html Fine Chemicals: The Industry and the Business – 2nd Edition, Wiley 2012]</ref><ref>[http://www.epmmagazine.com/x/guideArchiveArticle.html?gname=&browse=c&bid=461&id=11064  EPM Magazine]{{Dead link|date=January 2020 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{Cite web |url=http://www.specchemonline.com/articles/view/how-to-avoid-icebergs |title="How to avoid icebergs" – Speciality Chemicals Magazine |access-date=2013-03-06 |archive-url=https://web.archive.org/web/20121216051153/http://www.specchemonline.com/articles/view/how-to-avoid-icebergs |archive-date=2012-12-16 |url-status=dead }}</ref><ref>[http://www.macaomagazine.net/index.php?option=com_content&view=article&id=96:hovione&catid=39:issue-4   “A test tube in three continents” - Macao Magazine]</ref>
Hovione is a major source of [[semi-synthetic]] [[tetracycline]]s and [[corticosteroids]], and is the largest independent supplier of [[contrast agents]] – these three families of compounds make up most of its [[generic product]] portfolio. The other half of the business focuses on exclusive projects including the development of innovator APIs and particle engineering.<ref>{{Cite web |url=http://www.cleanroom-technology.co.uk/technical/article_page/Handling_potent_drug_materials/52867 |title="Handling potent drug materials" – Clean Room Technology |access-date=2013-03-06 |archive-url=https://web.archive.org/web/20120521082815/http://www.cleanroom-technology.co.uk/technical/article_page/Handling_potent_drug_materials/52867 |archive-date=2012-05-21 |url-status=dead }}</ref><ref>{{Cite web |url=http://www.drugdeliverytech-online.com/drugdelivery/201101#pg61 |title="What is special about inhalation APIs?" - Drug Delivery Technology |access-date=2013-03-06 |archive-url=https://web.archive.org/web/20130528173458/http://www.drugdeliverytech-online.com/drugdelivery/201101#pg61 |archive-date=2013-05-28 |url-status=dead }}</ref>
==Research and development==
Hovione has two [[R&D]] centers with a team of over 270 [[scientists]], one in [[Portugal]] - Loures and another one in its facilities in [[New Jersey]]. Hovione has international partnerships, including with [[Cambridge]] and [[MIT]].<ref>[https://www.mitportugal.org/events/event/94-hovione-mit-portugal-symposium-showcasing-portuguese-pharma-science    “Hovione & MIT Portugal Symposium: Showcasing Portuguese Pharma Science” - MIT Portugal]{{Dead link|date=August 2024 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> In 2016, 7 PhDs were simultaneously running and it launched a scientific program named "9oW",<ref>[https://www.jornaldenegocios.pt/empresas/industria/detalhe/hovione_disponivel_para_investir_cinco_milhoes_em_investigacao_em_portugal    “Hovione disponível para investir cinco milhões em investigação em Portugal” - Jornal Negócios]</ref> which challenges scientific and academic communities to help overcome technological challenges. Also, Hovione is already the largest private employer of doctorates in Portugal (57 doctorates in Loures).<ref>[https://www.dn.pt/portugal/interior/o-prazer-de-desenvolver-um-modelo-e-ve-lo-aplicado-em-dois-meses-5634538.html    “O prazer de desenvolver um modelo e vê-lo aplicado em dois meses” - DN]</ref>
== Strategy ==
Hovione was present in the pharmaceutical industry offering products and services related to the development and manufacture of either a [[new chemical entity]] (NCE) for an exclusive contract [[manufacturing]] partner or an existing API for an off-patent product. In the area of [[technologies|technology]], it has capabilities, among others, in [[spray drying]], controlled [[crystallization]], [[microfluidization]], and continuous tabletting.<ref>[http://www.prnewswire.com/news-releases/hovione-and-vertex-partner-in-continuous-manufacturing-571640001.html    “Hovione and Vertex Partner in Continuous Manufacturing” - Cision PR Newswire]</ref> Hovione invested about $100 million in 2017 and plans to spend as much again in 2019 and 2020. The plan over the next three years is to continue investing, especially in Portugal, where the firm will add 165 m<sup>3</sup> of chemical synthesis capacity, a spray-dryer building, and a 1,200-m<sup>2</sup> analytical lab.<ref>{{Cite web|url=https://cen.acs.org/business/outsourcing/Hovione-bulkstwist/96/i45|title=Hovione bulks up, with a twist|website=Chemical & Engineering News|language=en|access-date=2019-05-21}}</ref>
== References ==
{{Reflist}}
{{Authority control}}
[[Category:Pharmaceutical companies of Portugal]]
[[Category:Pharmaceutical companies established in 1959]]
[[Category:1959 establishments in Portugal]]
[[Category:Portuguese brands]]